Project Grant R35HL184169
- Federal Project Grant Award Summary Louisiana State University Health Sciences Center-Shreveport received a $479,600 project grant award dated September 1, 2025, from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The three-year research initiative, concluding August 31, 2028, investigates afferent baroreflex dysfunction in hypertension, with particular focus on understanding how arterial baroreceptors sense blood...
- Federal Project Grant Award Summary LSU Health Sciences Center-Shreveport received a $247,729 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with a completion date of June 30, 2028. This research project investigates the function and regulation of MEIS1 (Myeloid Ecotropic Viral Integration Site 1), a previously unrecognized transcription factor in vascular smooth muscle cells...
- Federal Grant Award Summary Louisiana State University Health Sciences Center-Shreveport received a $425,505 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion scheduled for May 31, 2030. This research project investigates the role of cell-specific Programmed Death-Ligand 1 (PD-L1) in cardiac pathophysiology following ischemic injury and explores the...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $248,679 to Louisiana State University Health Sciences Center-Shreveport on February 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This three-year research initiative, extending through January 31, 2029, focuses on elucidating the functional role and underlying mechanisms of HMGXB4 (High Mobility Group Box Domain Containing 4), an uncharacterized nuclear...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Louisiana State University Health Sciences Center-Shreveport a Project Grant of $659,441 under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic science research investigating nutrient sensing mechanisms in macrophage-mediated clearance of apoptotic cells. The research, which commenced August 15, 2025, and extends through May 31, 2029, seeks to elucidate the molecular pathways...
- Federal Project Grant Award Summary Louisiana State University Health Sciences Center New Orleans received a $374,576 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for August 31, 2027. This research project investigates the role of neutrophils in cystic fibrosis (CF) pathogenesis, addressing critical gaps in understanding how neutrophils acquire and...
- Federal Project Grant Award Summary Nusirt Sciences, Inc. received a $1,084,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for June 30, 2027. The award funds clinical validation research for NS-0200, a fixed combination drug product designed to treat hypertension. This research directly addresses a significant public health need, as...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Nevada, Reno a Project Grant totaling $694,723 (Award Date: September 1, 2025; Completion Date: June 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research on the regulation of capillary hemodynamics by thin-stranded pericytes. The research will characterize the ion channels, intracellular signaling pathways, and contractile machinery...
- Federal Grant Award Summary The University of Miami's Office of Research Administration received a $345,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026, with an ultimate completion date of February 28, 2028. This award supports basic and translational research investigating the role of gasdermin-D (GSDMD) in neonatal hyperoxia-induced vascular and cardiac dysfunction. The...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $130,065 Project Grant on July 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco. The award supports the REMOTE-BP (Research and Mentorship for Optimizing Treatment and Evaluation of Blood Pressure) initiative, which conducts systematic economic analyses of remote team-based hypertension care delivery models implemented...
Louisiana State University Health Sciences Center New Orleans received a $1,008,719 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 6, 2026, with a completion date of March 31, 2033. The award funds basic and translational research focused on screening and validating microRNA (miRNA) targets for neurogenic hypertension, a condition that is difficult to treat and contributes significantly to resistant hypertension in patient populations. The research builds on the institution's two decades of prior work investigating the brain renin-angiotensin system and aims to advance understanding of regulatory mechanisms affecting angiotensin-converting enzyme 2 (ACE2) compensatory activity, including post-translational modifications and protein degradation pathways mediated by E3 ligases in GABAergic neurons of the hypothalamic paraventricular nucleus. The project will generate scientific outputs expected to include detailed characterization of miRNA regulatory networks controlling ACE2 and related compensatory mechanisms in neurogenic hypertension models, identification of novel therapeutic targets for treating resistant hypertension, and mechanistic insights into central nervous system regulation of sympathetic outflow. Research findings will be disseminated through peer-reviewed publications and may inform the development of future therapeutic interventions to improve blood pressure control in patients with neurogenic and resistant hypertension.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.0m | 4/7/26 |